Meeting
2020 ASCO Virtual Scientific Program
First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI).
Presenter
Daniel Peter Petrylak, MD
Smilow Cancer Center, Yale University
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
New Targets and New Technologies (non-IO)
Clinical Trial Registration Number
NCT03888612
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3500)
DOI
10.1200/JCO.2020.38.15_suppl.3500
Abstract #
3500
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Genitourinary Cancers Symposium
Multi-centre prospective evaluation of cognitive function in patients with metastatic castrate-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) or enzalutamide (ENZ): The ACE study.
Speaker: Amit Bahl, MD, FRCP, FRCR
Speaker: Panel Discussion
Videos & Slides
2021 Genitourinary Cancers Symposium
PD-L1 inhibition with avelumab plus abiraterone acetate or enzalutamide in African Americans with metastatic castrate-resistant prostate cancer (mCRPC).
Speaker: Jodi Lyn Layton, MD
Speaker: Panel Discussion